DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101

MIRAMAR, Fla., July 27, 2026 /PRNewswire/ -- Agency issues "study may proceed" letter; development pathway does not require a clinical endpoint efficacy study. DifGen Pharmaceuticals LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's...